Midazolam Viatris

Midazolam, the active ingredient in Midazolam Viatris, is a benzodiazepine presented as a sterile solution for intramuscular, intravenous and rectal use. It provides rapid sedation and anticonvulsant effects for patients undergoing procedures, anesthesia induction, status epilepticus or severe anxiety.

GNH USA supplies Midazolam Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Midazolam is a benzodiazepine that acts on the central nervous system to produce sedation, anxiolysis and seizure control.

- Procedural sedation: provides rapid, controllable sedation for diagnostic or therapeutic procedures. - Induction of anesthesia: facilitates smooth induction and reduces airway reflexes before general anesthesia. - Status epilepticus: terminates ongoing seizures when first‑line therapies are insufficient. - Severe anxiety: produces marked anxiolysis in patients with acute, intense anxiety.

Midazolam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: excessive sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or unsteadiness. - Amnesia: short‑term memory loss surrounding the period of administration. - Nausea: feeling of stomach upset, sometimes leading to vomiting. - Respiratory depression: reduced breathing rate, especially at higher doses.

Serious or Rare Side Effects: - Severe respiratory depression or apnea requiring assisted ventilation. - Hypotension: significant drop in blood pressure. - Paradoxical reactions: agitation, aggression or involuntary movements. - Anaphylaxis: rare severe allergic response. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Midazolam requires careful clinical monitoring and patient assessment before and during use. - Assess respiratory function: monitor breathing rate, oxygen saturation and airway patency. - Avoid use in severe hepatic impairment: reduced clearance may increase toxicity. - Use caution in the elderly: increased sensitivity may lead to prolonged sedation. - Avoid concomitant CNS depressants: additive effects can cause profound sedation or respiratory compromise. - Pregnancy and lactation: consult a specialist before prescribing, as risks to fetus or infant are not fully defined. - Store at ambient temperature: keep in original container, protect from moisture and light.

Midazolam can interact with other medicines, altering its effects or safety profile.

Major Interactions (Avoid): - Opioids (e.g., morphine, fentanyl): combined use can cause profound respiratory depression. - Other benzodiazepines: additive sedation and risk of overdose. - Barbiturates: synergistic CNS depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase midazolam plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antidepressants (e.g., fluoxetine, sertraline): may enhance sedative effects.